Giant Biogene Holding Co (HKSE:02367) ROCE % : 48.57% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Giant Biogene Holding Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 48.57%.

Giant Biogene Holding Co ROCE % Historical Data

The historical data trend for Giant Biogene Holding Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co ROCE % Chart

Giant Biogene Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

57.88

102.95

129.97

59.00

47.43

Giant Biogene Holding Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-	94.90	46.52	48.03	48.57

Giant Biogene Holding Co ROCE % Calculation

Giant Biogene Holding Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1908.864	/	( ( (3504.502 - 313.691)	+	(5439.448 - 580.372) )	/ 2 )
	=	1908.864	/	( (3190.811	+	4859.076)	/ 2 )
	=	1908.864	/	4024.9435
	=	47.43 %

Giant Biogene Holding Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	2120.97	/	( ( (4241.702 - 367.771)	+	(5439.448 - 580.372) )	/ 2 )
	=	2120.97	/	( ( 3873.931	+	4859.076 )	/ 2 )
	=	2120.97	/	4366.5035
	=	48.57 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Giant Biogene Holding Co (HKSE:02367) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Giant Biogene Holding Co ROCE % Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN

Website

http://www.xajuzi.com

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines